Eton Pharmaceuticals Inc
NASDAQ:ETON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
US |
|
A
|
Advent-AWI Holdings Inc
OTC:AVDWF
|
CA |
|
N
|
NHN KCP Corp
KOSDAQ:060250
|
KR |
|
8
|
888 Holdings PLC
OTC:EIHDF
|
GI |
|
Beijing Bohui Science & Technology Co Ltd
SSE:688004
|
CN |
|
Innovotech Inc
XTSX:IOT
|
CA |
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
Revenue: Q4 product revenue was $21.3 million, up 83% year-over-year driven by Alkindi and newly relaunched products.
Profitability: GAAP net income was $1.5 million in Q4 and adjusted EBITDA was $6.2 million (29% margin); management expects materially higher full-year margins as revenue scales.
Guidance: 2026 revenue is expected to exceed $110 million; management gave an adjusted EBITDA margin target (management commentary varied between at least 3% and above 30% for full year commentary).
New launch: Desmoda (oral liquid desmopressin) launched after FDA approval; management is seeing strong early demand and reaffirmed a pediatric-driven $30M–$50M peak sales thesis while exploring incremental adult opportunity.
M&A: Eton acquired HEMANGEOL for $14 million in cash and plans a May 1 relaunch with a rare-disease distribution model and Eton Cares patient support to improve economics and access.
Pipeline & label work: Plans active clinical programs in 2026 including an Increlex label-harmonization study (protocol submitted, first patient expected in Q3) and a PET proof-of-concept for ET-700 with topline later this year.
Access & patient support: Eton Cares and zero-dollar copay programs are central to uptake strategies (Galzin reached 300 active patients; Alkindi/Khindivi franchise at ~12% penetration of a ~5,000 child target).
